Dyne Therapeutics gets FDA priority review for DMD drug z-rostudirsen
Dyne Therapeutics, Inc. announced that the FDA has accepted its BLA for zeleciment rostudirsen for Priority Review, targeting Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA set a PDUFA target action date of January 21, 2027, with a potential U.S. launch in Q1 2027. The therapy has received multiple regulatory designations, including Breakthrough Therapy and Orphan Drug status, and is supported by data from the DELIVER trial showing increased dystrophin production.
*this image is generated using AI for illustrative purposes only.
Dyne Therapeutics, Inc. has secured Priority Review from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) targeting Duchenne muscular dystrophy (DMD). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027, for zeleciment rostudirsen (z-rostudirsen), an investigational therapy designed for individuals with DMD amenable to exon 51 skipping. The company anticipates a potential U.S. launch in Q1 2027, subject to regulatory approval.
The submission for Accelerated Approval relies on dystrophin production as a surrogate endpoint. In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every four weeks resulted in a robust and statistically significant increase in dystrophin. The trial data also indicated functional improvement across multiple clinical endpoints and a favorable safety profile.
Regulatory Designations and Trial Status
Z-rostudirsen has received several regulatory designations intended to expedite development and review. These include Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA. Additionally, the therapy holds Orphan Drug designation from the FDA, the European Medicines Agency (EMA), and the Ministry of Health, Labour and Welfare (MHLW) in Japan.
The therapeutic continues to be evaluated in the long-term extension portion of the DELIVER trial. A global confirmatory Phase 3 trial, known as FORZETTO, is also underway to further assess the drug's efficacy and safety.
Pipeline Expansion
Beyond the lead candidate, Dyne is advancing a broader franchise for DMD. The company is developing four additional candidates targeting other exons:
| Candidate | Target Exon |
|---|---|
| DYNE-253 | Exon 53 |
| DYNE-245 | Exon 45 |
| DYNE-244 | Exon 44 |
| DYNE-255 | Exon 55 |
Mechanism of Action
Z-rostudirsen consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an antigen-binding fragment (Fab). This Fab binds to the transferrin receptor 1 (TfR1), facilitating the delivery of the therapy to muscle and the central nervous system (CNS). The mechanism is designed to enable the production of near-full length dystrophin, aiming to provide functional improvement for patients.
What are the potential commercial advantages of Dyne's proprietary Fab-PMO delivery mechanism compared to existing exon-skipping therapies for DMD?
How will the outcome of the ongoing FORZETTO Phase 3 confirmatory trial influence the FDA's final decision on the Accelerated Approval pathway?
What is the projected market share for z-rostudirsen given the current competitive landscape for exon 51 skipping therapies?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
